The biological drug TSO is a liquid suspension that is simply administered orally a few times per months.
The natural biological, and unmodified, ingredient is Trichuris suis ova (TSO).
Substantial research demonstrates that TSO stimulate the gut microbiome (microbial communities) and trigger a series of favourable immune response which reduces chronic inflammation.
ParaTech conducts state-of-the-art clinical trials to prove efficacy of the biological drug TSO. TSO have been tested in several clinical trials under EMA and FDA for several autoimmune indications (phase 1 and 2).
Overall, the clinical trials have proven that TSO has a mild safety profile and promissing effect.
In 2018, a phase 2b trial in ulcerative colitis (UC) has started.